Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Kezar Life Sciences (KZR) Operating Expenses (2021 - 2025)

Historic Operating Expenses for Kezar Life Sciences (KZR) over the last 5 years, with Q2 2025 value amounting to $14.6 million.

  • Kezar Life Sciences' Operating Expenses fell 3756.58% to $14.6 million in Q2 2025 from the same period last year, while for Sep 2025 it was $53.8 million, marking a year-over-year decrease of 4809.37%. This contributed to the annual value of $90.6 million for FY2024, which is 2349.1% down from last year.
  • Latest data reveals that Kezar Life Sciences reported Operating Expenses of $14.6 million as of Q2 2025, which was down 3756.58% from $17.6 million recorded in Q1 2025.
  • In the past 5 years, Kezar Life Sciences' Operating Expenses registered a high of $34.6 million during Q4 2023, and its lowest value of $13.0 million during Q2 2021.
  • For the 5-year period, Kezar Life Sciences' Operating Expenses averaged around $20.8 million, with its median value being $20.0 million (2022).
  • Per our database at Business Quant, Kezar Life Sciences' Operating Expenses skyrocketed by 7265.15% in 2023 and then tumbled by 3765.94% in 2024.
  • Over the past 5 years, Kezar Life Sciences' Operating Expenses (Quarter) stood at $14.1 million in 2021, then soared by 42.05% to $20.0 million in 2022, then skyrocketed by 72.65% to $34.6 million in 2023, then plummeted by 37.66% to $21.6 million in 2024, then plummeted by 32.3% to $14.6 million in 2025.
  • Its last three reported values are $14.6 million in Q2 2025, $17.6 million for Q1 2025, and $21.6 million during Q4 2024.